The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2023 | BRUIN CLL-322: pirtobrutinib plus VR vs VR alone in R/R CLL
Jennifer Woyach, MD, Ohio State University College of Medicine, Columbus, OH, comments on BRUIN CLL-322 (NCT04965493), a Phase III open-label, randomized study comparing fixed duration pirtobrutinib plus venetoclax and rituximab (VR) with a standard regimen of VR in previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study aims to determine whether pirtobrutinib will provide additional efficacy when administered alongside the standard of care regimen for relapsed/refractory (R/R) CLL. This interview took place at the biennial International Workshop on Chronic Lymphocytic Leukemia (iwCLL) 2023 meeting, held in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
